A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus

Inclusion Criteria: * Type 2 diabetes mellitus ≥ 12 months * Treated with stable multiple daily insulin ≥ 3 months (basal-bolus therapy or only bolus insulin therapy) * Current total daily insulin treatment \<1.2 (I)U/kg/day * Body Mass Index below or equal to 40.0 kg/m² * HbA1c ≤ 9.0% by local laboratory analysis Exclusion Criteria: * Known or suspected hypersensitivity to trial products or related products * Type 1 diabetes mellitus * Previous participation in this trial * The receipt of any investigational product within 60 days prior to this trial * Clinically significant abnormal haematology, biochemistry, lipids, or urinalysis screening tests, as judged by the Investigator considering the underlying disease * Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea), as judged by the Investigator * Presence of renal impairment (Estimated Glomerular filtration Rate (eGFR)\<60 milliliters/minute/1.73m²) * Presence of late diabetic complications and/or acute coronary heart disease. * Known slowing of gastric emptying and or gastrointestinal surgery that in the opinion of the investigator might change gastrointestinal motility and food absorption * Unusual meal habits and special diet requirements or unwillingness to eat the food provided in the trial * Current treatment with corticosteroids